Compass Therapeutics (NASDAQ:CMPX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Other equities analysts also recently issued reports about the stock. Leerink Partnrs upgraded shares of Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. William Blair initiated coverage on Compass Therapeutics in a research report on Monday, January 5th. They set an “outperform” rating on the stock. Lifesci Capital began coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target on the stock. Citizens Jmp started coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective for the company. Finally, Canaccord Genuity Group began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They set a “buy” rating and a $10.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.23.

Compass Therapeutics Trading Down 1.7%

Shares of Compass Therapeutics stock opened at $5.70 on Friday. The stock’s fifty day moving average price is $5.19 and its 200-day moving average price is $4.03. The firm has a market cap of $1.01 billion, a P/E ratio of -12.67 and a beta of 1.45. Compass Therapeutics has a 12 month low of $1.33 and a 12 month high of $6.25.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC raised its stake in Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after buying an additional 6,951,666 shares during the last quarter. Vivo Capital LLC increased its holdings in shares of Compass Therapeutics by 57.9% during the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after acquiring an additional 3,502,000 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after purchasing an additional 2,212,794 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after purchasing an additional 2,386,367 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.